Discovery Laboratories (NASDAQ:DSCO) is a biotechnology company focused on developing products for the treatment of respiratory disease. DSCO also gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of DSCO stock.

NovaGold Resources (AMEX:NG) explores and develops mineral properties in North America. NG also gets an F in Equity. Since January 1, NG has fallen 44.5%. For more information, get Portfolio Grader’s complete analysis of NG stock.

Sunesis Pharmaceuticals (NASDAQ:SNSS) is a clinical-stage biopharmaceutical Company which focuses on the discovery, development and commercialization of novel small molecule therapeutics for oncology. SNSS also gets F’s in Earnings Growth, Analyst Earnings Revisions, Equity, and Cash Flow. For more information, get Portfolio Grader’s complete analysis of SNSS stock.

AVEO (NASDAQ:AVEO) engages in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform. AVEO gets F’s in Earnings Growth, Earnings Momentum, Equity, Cash Flow, and Operating Margin Growth as well. Since January 1, AVEO has fallen 44.9%. This is worse than the Nasdaq, which has seen a 18.1% increase over the same period. For more information, get Portfolio Grader’s complete analysis of AVEO stock.

Navidea Biopharmaceuticals (AMEX:NAVB) is focused on the development and commercialization of precision radiopharmaceutical diagnostics for diseases such as cancer. NAVB also gets an F in Equity. The stock has a trailing PE Ratio of 121. For more information, get Portfolio Grader’s complete analysis of NAVB stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.